N/A N=784 Healthcare Utilization in Obese Caregiver Living Donors
Utilization, Health Care · Obesity
Primary: Emergency Department Utilization — 77; 305 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=70 Evaluation of the Spectra Optia® Apheresis System Mononuclear Cell (MNC) Collection Procedure in Healthy Blood Donors
Leukapheresis
Primary: Mononuclear Cell Collection Efficiency — 61; 57 % of processed MNCs that were collected
Phase 2 N=116 Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants
Chronic Myelogenous Leukemia · Acute Myelogenous Leukemia · Chronic Lymphocytic Leukemia
Primary: Survival and Non-relapse Mortality at Day +200 Using the Miltenyi Reagent System — 43; 4 participants
N/A N=197 Iron Depletion and Replacement in Blood Donors
Anemia
Primary: Number of Participants With Adherence to Iron Replacement Therapy at Subsequent Donation — 116; 17 Participants
N/A N=72 Don't Throw Your Heart Away: Clinician Study 3
Cardiac Transplant Disorder
Primary: Hospital Choice — 4; 21; 34; 13 Participants
N/A N=105 Don't Throw Your Heart Away: Medical Student Study 2
Cardiac Transplant Disorder
Primary: Hospital Choice — 33; 47; 23; 2 Participants
Phase 2 N=73 Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
Leukemia, Acute Lymphocytic (ALL) · Leukemia, Myeloid, Acute(AML) · Leukemia, Myeloid, Chronic(CML)
Primary: Event-free Survival (EFS) — 54.8 Percentage of participants
N/A N=44 Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
Hematologic Malignancy
Primary: Proportion of Patients Undergoing an Allo HCT Transplant Who Have a KIR Favorable Donor. — 23; 21 Participants
Phase 3 N=838 Intravenous Thyroxine for Heart-Eligible Organ Donors
Brain Death · Heart Failure
Primary: Heart Transplanted — 230; 223 Participants — p=0.57
N/A N=22 Survival and Recovery of Radio-labeled Platelets Derived From Mirasol-treated Whole Blood
Blood Safety
Primary: Platelet 24-hour Relative Recovery — 43.31; 52.01 Percentage of platelet count
N/A N=79 Donor Iron Deficiency Study - Red Blood Cells From Iron-deficient Donors: Recovery and Storage Quality
Iron Deficiency
Primary: 51-Chromium 24-hour Post-transfusion RBC Recovery of Units — 1.6; -0.4 percentage change
Phase 4 N=25 HCV Positive Heart Donors
Heart Failure
Primary: Sustained Virologic Response After Treatment — 24 Participants
N/A N=77 Clinical Evaluation of the CM-1500 During Apheresis Blood Donation
Fluid Loss
Primary: Characterize Changes in the Relative Index During an Apheresis Procedure — 94.9; 99.3 Relative Index
N/A N=180 Donors After Circulatory Death Heart Trial
Heart Transplant
Primary: Survival — 76; 75 Participants — p=<0.0001
N/A N=321 Remote Ischemic Preconditioning in Neurological Death Organ Donors
Organ Transplantation
Primary: Number of Organs Recovered Per Donor — 3.79; 3.60 organs recovered per donor — p=0.38
N/A N=36 Nutritional Status and Enteral Absorption Capability After Brain Death
Brain Death
Primary: Primary Outcome Measure is IL-6 Level — 565.5; 264.9 pg/ml
N/A N=1,019 Don't Throw Your Heart Away: Layperson Study 1
Cardiac Transplant Disorder
Primary: Hospital Choice — 64; 125; 163; 192 Participants
N/A N=223 Bloodsafe Ghana- Iron and Nutritional Counseling Strategy Pilot Study
Iron-deficiency Anemia · Iron-deficiency
Primary: Haemoglobin Level — 11.35; 12.28 g/dL — p=0.025
Phase 2 N=38 Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell Donors
Cytomegalovirus Infections
Primary: Cellular Immune Response in Vaccine Recipients — 14 participants
Phase 2 N=16 DCreg in Living Donor Liver Transplantation
Living Donor Liver Transplantation
Primary: Proportion of Safety Events — 1 Participants
N/A N=7 Donor-Derived Humoral Immunity, Hematopoietic Stem Cell Transplantation, TAR
Acute Lymphoblastic Leukemia · Acute Myelogenous Leukemia · Chronic Myelogenous Leukemia
Primary: Antibody Recall Response Rate — 0.167 proportion of participants
Phase 2 N=40 Preventing Stem Cell Transplant Complications With a Blood Separator Machine
MDS (Myelodysplastic Syndrome) · Myeloproliferative Disorder · Lymphoma, Non-Hodgkin
Primary: Overall Survival — 36 Participants
Phase 1 N=170 Evaluation of Whole Blood With CPD Anticoagulant and AS-7/SOLX Additive Solution
Blood Donors
Primary: Red Blood Cell Post-filtration Recovery — 92.57; 92.70; 90.96; 90.23 % recovery at day 0
Phase 2 N=15 Donor Alloantigen Reactive Tregs (darTregs) for Calcineurin Inhibitor (CNI) Reduction
Liver Transplant Recipient · Living Donor (of the Respective Liver Transplant Recipient)
Primary: Number of Participants Who Experienced Grade 3 or Higher Adverse Events (AEs) Deemed Attributable to darTreg Infusion — 0 Participants
Phase 2 N=54 Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant
Multiple Myeloma · Lymphocytic Leukemia, Chronic · Lymphoma, Low-Grade
Primary: Percentage of Participants With Acute Graft Versus Host Disease (GVHD) Grades 2-4 — 73 percentage of participants
Phase 2 N=82 Haploidentical Donor Hematopoietic Progenitor Cell and NK Cell Transplantation for Hematologic Malignancy
Leukemia · Lymphoma
Primary: Number of Transplant Recipients With Successful Engraftment — 70 Participants
N/A N=90 Donor After Circulatory Death Heart CAP Trial
Heart Transplant
Primary: Patient Survival — 75 Participants
Phase 2 N=46 T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
Acute Lymphoblastic Leukemia · Non Hodgkins Lymphoma · Myelodysplastic Syndrome
Primary: Engraftment Rate After Transplant — 100; 100 percentage of participants
N/A N=3 CD34+ Cell Enriched and T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Mismatched Related Donors or Borderline Organ Function
Malignant Diseases · Non-malignant Diseases
Primary: Number of Patients With Severe (Grade III/IV) Acute Graft vs Host Disease (GVHD) — 0 Participants
N/A N=50 Sucrosom5al Iron Supplementation in Blood Donors
Iron-deficiency
Primary: Hb (g/dl) at E2 — 13.07 g/dl — p=0.031